NHS England's approval of two groundbreaking drugs for rare blood cancers is set to bring hope and potentially life-changing treatment options to hundreds of patients, including young children and infants. For families who have seen their loved ones' conditions worsen despite previous treatments, this news comes as a beacon of light in an otherwise challenging journey.
The first drug, dabrafenib, targets histiocytic neoplasms – aggressive blood cancers that affect only a small number of people. By inhibiting the proteins that fuel cancer growth, this tablet treatment can slow or halt disease progression. One of the most significant benefits is that many patients will be able to take it at home, reducing hospital visits and minimizing disruption to daily life.
A staggering one in ten children with high-risk histiocytic neoplasms die within a year of diagnosis, while seven in ten adults succumb to the disease within five years. The approval of dabrafenib underscores the urgent need for more effective interventions like this targeted therapy, which can make a significant difference in outcomes.
The second approval involves a new combination treatment for children as young as eight with Hodgkin lymphoma that has relapsed or not responded to initial therapies. This disease affects approximately 1,800 people in England annually, with between 10% and 30% experiencing a recurrence or non-response to standard treatment.
The innovative regimen combines brentuximab vedotin and bendamustine, which precisely targets cancer cells by binding to a surface protein. Administered via an intravenous drip, this combination has shown high remission rates and is generally well-tolerated, enabling some patients to undergo a potentially curative stem cell transplant.
Professor Peter Johnson hailed the approvals as a "landmark moment" in cancer treatment, highlighting the access to new options and the renewed hope these therapies offer. He emphasized that allowing many patients to receive treatment at home aligns with the NHS's commitment to improving quality of life.
NHS England's Clinical Priorities Advisory Group played a crucial role in assessing these specialist medicines, considering their patient benefit, clinical effectiveness, and value for money. The group noted significant advances in understanding these disorders, particularly the discovery of genetic drivers that have paved the way for targeted therapies like BRAF and MEK inhibitors.